A61K 31/282
Platinum compounds
A61K31/282 (Platinum compounds) appears on 783 US grants and 1,658 published applications in this corpus.
Search patents in A61K- Granted patents
- 783
- Published applications
- 1,658
- Assignees
- 788
- Inventors
- 3,024
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 2 | 1 |
| 2002 | 4 | 3 |
| 2003 | 2 | 9 |
| 2004 | 6 | 21 |
| 2005 | 3 | 19 |
| 2006 | 9 | 34 |
| 2007 | 3 | 53 |
| 2008 | 5 | 46 |
| 2009 | 9 | 44 |
| 2010 | 18 | 54 |
| 2011 | 21 | 43 |
| 2012 | 19 | 48 |
| 2013 | 30 | 70 |
| 2014 | 35 | 90 |
| 2015 | 52 | 81 |
| 2016 | 54 | 89 |
| 2017 | 50 | 104 |
| 2018 | 48 | 85 |
| 2019 | 68 | 114 |
| 2020 | 62 | 102 |
| 2021 | 54 | 116 |
| 2022 | 47 | 107 |
| 2023 | 38 | 76 |
| 2024 | 43 | 105 |
| 2025 | 57 | 77 |
| 2026 | 31 | 67 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Imidazole-based synthetic lipidoids for in vivo mRNA delivery into immune cells29 Sep 2026US 12,747,214 B2Trustees of Tufts College
- Methods of treating breast cancer15 Sep 2026US 12,738,355 B2City of Hope
- Method of treating triple-negative breast cancer25 Aug 2026US 12,714,691 B2Dana-Farber Cancer Institute, Inc.
- Compositions and methods for cancer therapy25 Aug 2026US 12,714,723 B2AIM ImmunoTech Inc.
- Methods and materials for assessing loss of heterozygosity7 Jul 2026US 12,674,207 B2Board of Regents, The University of Texas System
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs1 Oct 2026US 2026/0295040 A1Merus N.V.
- Use of Amivantamab to Treat Head and Neck Cancer1 Oct 2026US 2026/0295041 A1Janssen Biotech, Inc.
- Methionine adenosyltransferase 2a (mat2a) inhibitor combinations and uses thereof24 Sep 2026US 2026/0284051 A1Insilico Medicine IP Limited
- Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin24 Sep 2026US 2026/0284054 A1Ipsen Biopharm Ltd.
Most cited
By later US patents
- Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies166US 6,949,245 B1Genentech, Inc. · 2005
- Combinations and modes of administration of therapeutic agents and combination therapy131US 8,034,375 B2Abraxis BioScience, LLC · 2011
- Combinations and modes of administration of therapeutic agents and combination therapy119US 7,758,891 B2Abraxis BioScience, LLC · 2010
- Combinations and modes of administration of therapeutic agents and combination therapy116US 8,735,394 B2Abraxis BioScience, LLC · 2014
- Combinations and modes of administration of therapeutic agents and combination therapy107US 8,268,348 B2Abraxis BioScience, LLC · 2012